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ABSTRACT
Objectives: To investigate the impact of adopting pharma-
ceutical innovations on the growth of pharmaceutical expen-
ditures, focusing speciﬁcally on Taiwan’s experience.
Methods: We ﬁrst provide a descriptive analysis of cost
impacts of introducing new drugs into Taiwan’s national
formulary using data from Taiwan. We then use a statistical
method to decompose the growth of pharmaceutical expen-
ditures during 1997–2001 into three components: 1) treat-
ment expansion; 2) treatment substitution; and 3) price
effect. By incorporating the estimated beneﬁt from prior
studies, we calculate the incremental cost-effectiveness ratio
for new drugs as a whole.
Results: We ﬁnd that from 1997 to 2001 public expenditures
on pharmaceuticals grew 57%. The primary drivers of this
expenditure growth were treatment expansion and treatment
substitution. Prices declined by 18%. Cost per life-year
gained resulting from introduction of new drugs was
US$1053 (in 2003 dollars) from the perspective of the public
payer and US$1824 from the perspective of society as a
whole.
Conclusions: Overall, our analysis provides evidence with
previous studies that the drug reimbursement price is not the
primary driver of increased spending. Rather the introduc-
tion of new drugs into the formulary leading to expansion of
treatment, expansion and substitution of the new drugs for
existing drugs may increase spending. Although the adoption
of pharmaceutical innovation is costly, the estimated beneﬁt
of adopting pharmaceutical innovation generally far exceeds
the cost, indicating that the adoption of pharmaceutical inno-
vation is on the whole worthwhile.
Keywords: drug expenditure, pharmaceutical innovation,
treatment expansion, treatment substitution.
Introduction
Technological change in medicine has been a major
cause of rising health-care expenditures in many
countries [1]. A substantial amount of technological
progress in medicine has taken the form of pharma-
ceutical innovation. Consequently, both spending on
prescription drugs and the share of drug expenditure in
total health-care expenditures have increased rapidly
in recent years [2–4]. Around the world, governments
have used a number of regulatory mechanisms to
control spending on pharmaceuticals [4]. Nevertheless,
there is a growing body of empirical evidence that
technological advances in the form of new prescrip-
tion drugs have made a substantial contribution to
increased longevity and improved quality of life [5–7].
Thus, there is an inherent conﬂict between the regula-
tory goal of controlling health-care budgets and
improving population health.
The purpose of this study is to use the experience
of Taiwan as an example to investigate the impact of
adopting pharmaceutical innovations on the growth of
pharmaceutical expenditures and whether pharmaceu-
tical innovation is worth the increased cost. There are
several advantages of using Taiwanese data to quantify
the impact of pharmaceutical innovation on health-
care costs. First, Taiwan has a social insurance system
providing universal insurance coverage. The National
Health Insurance (NHI) plan offers comprehensive
beneﬁts, including physician services, hospital care,
and prescription drugs. To control the cost of public
insurance, the government in Taiwan regulates the
price paid by the single health insurance plan for indi-
vidual drugs. The single-payer system allows policy-
makers as well as researchers to trace the impact of
introducing new drugs on national health costs.
Second, under a system of NHI, Taiwan has estab-
lished a national formulary (positive list), which
includes all pharmaceuticals subject to reimbursement
by NHI. Because the government imposes direct price
controls on pharmaceuticals by ﬁxing the prices
product by product, the numbers of drugs included in
the formularies are extraordinary large. There are
more than 21,000 drugs included in the NHI formu-
laries in Taiwan. The detailed list of drug formulary
allows the researcher to decompose the source of
expenditure growth on prescription drugs.
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Third, Taiwan spends about one quarter of health-
care expenditures on pharmaceuticals. As compared
to other developed countries, the higher spending
makes prescription drugs be more likely to become
the target of cost containment. As a result, the expe-
rience of Taiwan provides a valuable insight on
understanding how policymakers struggle with the
conﬂict between short-run cost impact and long-run
health beneﬁt.
The focal points of this article are threefold. We ﬁrst
brieﬂy discuss institutional details of Taiwan’s phar-
maceutical policies and describe the cost implications
of introducing new prescription drugs. We then
decompose the growth of pharmaceutical expenditures
during 1997–2001 into three components. The ﬁrst is
the growth of expenditures on prescription drugs
attributable to an increase in quantity of prescribed
drugs—the treatment expansion effect. Second, tech-
nological change may lead to shifts in drug use within
speciﬁc therapeutic category, especially to more expen-
sive products—the treatment substitution effect. The
third is the effect of price changes on pharmaceutical
expenditure—pure price effect.
By incorporating the estimated beneﬁt from the
existing study into our cost measurement, we also
calculate the incremental cost-effectiveness ratio for
new drugs as a whole. Speciﬁcally, we compare spend-
ing on new drugs per capita with average annual
increase in life expectancy attributable to new drug
launches.
Institutional Background
Characteristics of Pharmaceutical Market
There are two distinguishing characteristics of health-
care system that shape the structure of pharmaceutical
market in Taiwan. First, physicians dispense the drugs
that they prescribe. Thus, they are in a position to
proﬁt directly from the sales of prescription drugs. The
government regulates the reimbursement price, i.e.,
the price paid on behalf of patients, but do not regulate
the acquisition prices that hospitals or physicians prac-
ticing in clinics purchase drugs from the pharmaceuti-
cal manufacturers. Thus, hospitals or clinic physicians
receive the proﬁt margin between the reimbursement
and the acquisition prices.
Second, the medical staff is employed by the hospi-
tal. Also, patients are free to choose their own provid-
ers; there is no gatekeeper mechanism. Under this
system, except for emergencies, the main source of
inpatients is the outpatient department at the same
hospital. Thus, hospitals in Taiwan have a strong
incentive to operate large outpatient departments to
increase their inpatient ﬂows. Larger hospitals often
possess substantial bargaining power with pharmaceu-
tical manufacturers and can obtain drugs at a lower
acquisition price. In general, the proﬁt margin between
the reimbursement price and the acquisition price rep-
resents a major source of hospital revenue.
These two characteristics have had several impor-
tant consequences in the pharmaceutical markets in
Taiwan. First, the existence of proﬁt margins for
pharmaceuticals has led to distortions in relative
prices of prescription drugs and other health-care ser-
vices. Compared to prescription drugs, other health-
care services, such as production of diagnostic
information and surgical treatment, are very labor
intensive. In contrast to physical products, there is no
wholesale market for services, and hence providers
do not have an opportunity to earn a proﬁt margin
between the reimbursement and the acquisition
prices. With a positive margin on prescription drugs,
providers have a ﬁnancial incentive to substitute pre-
scription drugs for other inputs, such as time spent in
diagnosis or in surgical treatment. Spending on phar-
maceuticals consequently accounts for one quarter of
health-care expenditures in Taiwan. In 2004, the
share of health-care expenditures spent on drugs
ranged from 9% to 30% among OECD countries [8].
Although many other factors also account for the
international variation in the share of pharmaceutical
spending, the existence of proﬁt incentives in pre-
scribing drugs provides a plausible explanation for
the relatively higher share of drug expenditures
observed in Taiwan.
Second, although reimbursement prices are ﬁxed by
government, there is price competition in the whole-
sale market. Given the proﬁt that providers can earn
from the sale of drugs, the proﬁt margin between the
reimbursement and the acquisition price becomes the
important factor in the drug prescribing decisions.
Since there are many drugs within a therapeutic group,
the pharmaceutical manufacturers compete by cutting
acquisition prices. Of course, the lower limit on such
prices is marginal cost of manufacturing and distrib-
uting the drugs. Providers in turn only select the drugs
with higher proﬁt margins into their prescription
formularies.
Price competition in the wholesale market has
driven many products from the market (Table 1).
Although there are 21,931 drugs listed in the Taiwan’s
national formulary, only about 75% of products are
actually sold in a given year. In addition, the distribu-
tion of market size (in terms of annual expenditures)
by product is highly skewed. About 3700 drugs, or
17% of products listed in the national formulary,
account for about 97% of expenditures on pharma-
ceuticals. The prescriber’s proﬁt incentive shifts price
competition from the retail to the wholesale market
with the result that only about 3700 drugs remain
actively sold in the market. In monetary terms, the
annual market size is greater than one million Taiwan
dollars (or about US$30,000).
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Pricing and Cost Impact of New Drugs
New pharmaceutical products are introduced annually
as a consequence of technological advances. In addi-
tion to obtaining authorization to market a new drug,
Taiwan, like other countries with direct price controls
on pharmaceutical products, requires that the manu-
facturer of a new drug obtain approval for coverage
and a price for reimbursement by the Bureau of
National Health Insurance (BNHI) [4,9,10]. Taiwan
has not formally employed economic evaluation to
establish prices for new drugs to be included on its
formulary. Rather, BNHI adopts a mix of strategies to
determine the reimbursement price for new drugs,
including reference to existing products and to inter-
national comparisons, and the drug’s therapeutic
value.
BNHI uses the median price of international com-
parisons to set the cap on regulated prices for branded
drugs still on patent. For off-patent branded drugs, the
price cap is 85% of international median prices. For
generic drugs, the price cap is the mean price of the
branded price in the same therapeutic group if the drug
has passed a bio-equivalent test and 85% of the mean
price of the branded drugs in the same therapeutic
group if a bio-equivalent test is not conducted for the
drug. The BNHI selects 10 countries as the reference
group for international comparisons, including
Australia, Belgium, Canada, France, Germany, Japan,
Sweden, Switzerland, United Kingdom, and the United
States [11].
Many forms of new prescription drugs are added
to the national formulary annually, including new
molecular entities, formulations, combinations, and
indications. As a single payer, BNHI can trace all
expenditures on drugs as well as other health-care
services through its electronic administrative system.
Table 2 summarizes the expenditure and number of
new drugs included in the national formulary between
1996 and 2003. A new drug is deﬁned here as one that
was included in the national formulary after 1996.
During 1996–2003, the annual number of new
drugs included in the national formulary has ranged
from 13 to 75. On average, each drug cost about NT$
21–59 million annually (1 US$ equaled about 27.5–
34.6 NT$ during this period). Judging from the
average market size per drug in Taiwan, the annual
mean cost per new drug is very signiﬁcant. For
example, as shown in Table 1, there were only 717
products in Taiwan’s market (3.2% of total number of
products listed in the formulary) for which annual
expenditure on individual drug exceeded NT$20
million. Thus, the cost impact of introducing new
drugs was substantial relative to the mean national
level. Furthermore, the average annual growth rate of
Table 1 The distribution of pharmaceutical spending by market size
Market size
in 2001
(NT dollar)
Number
of drugs
Percentage of
total number
of drug (%)
Pharmaceutical
spending (in
million NT dollar)
Percentage of total
pharmaceutical
spending (%)
Greater than 100 million 129 0.59 25,666 37.90
50–100 million 178 0.81 12,230 18.06
20–50 million 410 1.87 12,780 18.75
10–20 million 474 2.16 6,617 10.38
1–10 million 2,536 11.56 9,005 13.49
Less than 1 million 12,684 57.84 1,382 2.07
0 (no sale) 5,520 25.17 0 0
Total 21,931 100.00 66,730 100.00
Source: Bureau of National Health Insurance,Taipei,Taiwan.
Note:The exchange rate of US$/NT$ was 34.42 in 2003.
Table 2 Expenditures and number of new drugs included in the National Health Insurance formulary*
Year
Number of
new drugs
Mean annual expenditure
per drug between
introduction year and
2003 (in million NT dollar)
Mean annual growth
rate of expenditure
between introduction
year to 2003 (%)
Total expenditure
on new drugs
(in million
NT dollar)
Spending on new
drugs as percent
of total spending in
pharmaceuticals
1996 13 59 40 — —
1997 54 21 24 473 0.99
1998 75 47 49 1,933 3.49
1999 42 30 64 4,063 6.42
2000 36 54 190 6,121 9.23
2001 73 40 229 8,431 12.45
2002 56 32 216 12,863 16.67
2003 50 — — 16,694 20.92
Source: Bureau of National Health Insurance,Taipei,Taiwan.
Note: 1.The deﬁnition of new drugs includes 1) new molecular entity; 2) new formulation; 3) new combination; and 4) new indication. 2.The exchange rate of US$/NT$ was 34.42
in 2003.
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drug expenditure for new products between the years
of introduction to 2003 ranged form 24% to 229%
(Table 2). A shorter observational period was associ-
ated with a higher growth rate. This suggests that the
introduction of new drug is not only costly in the short
run, but also in the longer run. For example, in 1998,
75 new drugs were included into the formulary and the
mean annual growth rate of expenditure was 49%
from 1998 to 2003, substantially more than the mean
annual growth rate of overall expenditures on phar-
maceuticals (6.4%). By 2003, total spending on 399
new drugs introduced into the national formulary after
1996 was about NT$17 billion, accounting for 21% of
total drug expenditures in that year. This indicates that
on average introducing a new drug into the formulary
costs about NT$42 million (17,000/399) per year.
As suggested by Cutler and McClellan [12], new
technology in medicine affects the cost of health care
through the two channels: a treatment substitution
effect and a treatment expansion effect. In the context
of pharmaceuticals, a treatment substitution effect
describes substitution of new drugs for older ones for
treating established patients. Because of the high costs
of pharmaceutical innovation which is partly reﬂected
in high prices because of the patent system, the price of
new drug is higher than for older drugs, at least some
of which are no longer patented. Thus, the treatment
substitution effect always leads to increased pharma-
ceutical expenditures [13,14]. The treatment expan-
sion effect indicates that the introduction of new drugs
into the formulary leads more people to be treated for
disease. Hence, the treatment expansion effect also
leads to increased pharmaceutical expenditure. In the
next section, we will use a statistical method to decom-
pose the growth of pharmaceutical expenditure into
treatment substitution effect and expansion effect.
Decomposition of the Source of
Expenditure Growth
Previous Studies
The rapid increase in pharmaceutical expenditure has
led to a search for the primary determinants of this
increase. By deﬁnition, pharmaceutical expenditures
are the product of prices and demand (quantity of
prescription pharmaceuticals consumed). The demand
for drug in turn depends on several factors, such as
drug insurance beneﬁt coverage, income, the incidence
and duration of chronic diseases, and technological
advances in medicine.
In practice, the relative importance of the above-
mentioned factors varies with country-speciﬁc aspects
of the health-care system and pharmaceutical policy in
each country. For example, in a country in which gov-
ernment does not regulate pharmaceutical prices
directly, such as the United States, price increases may
have a relatively important role in accounting for
expenditure growth. There is evidence that some phar-
maceutical manufacturers adopt a penetration strategy
to launch their new drugs that leads to an upward
sloping price curve over time [15].
By contrast, in some countries in which govern-
ments impose direct controls on product prices, such
as Japan and Sweden, price-cap regulation rules out
the use of penetration strategies [16,17]. Real (relative
to a consumer price index for all goods and services)
prices of drugs often fall over time as a result of gov-
ernment regulation and price-cutting. In these coun-
tries, price increases have not been an important cause
of increased expenditures. Similarly, the introduction
of insurance coverage for prescription drugs is an
important factor in accounting for expenditure growth
in countries in which private and/or public drug insur-
ance beneﬁt coverage has gradually been added. For
example, in 1965, only 3.5% of the US prescription
drug expenditure was paid by private insurance. By
1998, the private plus Medicaid insurance share
increased to 69.8% [3]. The empirical evidence shows
that the growth in the US pharmaceutical expenditure
closely paralleled this expanded drug insurance cover-
age [18]. But health insurance is not the primary driver
of increased spending in countries that insurance cov-
erage for prescription drugs had remained constant
over time, such as Japan and Taiwan.
Given that the major cause or causes of increased
spending varies across countries and over time, several
studies have sought to identify the underlying drivers
of spending trends by decomposing the sources of
expenditure growth [2,3,19,20]. Dubois et al. [2] used
large claims databases from managed care and the
employer-sponsored health beneﬁt plans in the United
States to disaggregate the growth of drug spending
between 1994 and 1998 into several price and volume
factors. They decomposed the change in price into
three components: 1) pure inﬂation (measuring by an
index of change in actual transaction prices); 2) price
change because of the change in dosage strength and
therapeutic mix; and 3) change in mean price per day
on account of the introduction of new drugs. For
volume, they calculated these three measures: 1)
changes in the number of prescriptions per person; 2)
changes in the number of days supplied per prescrip-
tion; and 3) changes in the number of users and poten-
tial users of prescription drugs per thousand plan
members, which they used as a measure of prevalence
of the disease. In their study, users were deﬁned as
patients treated with a particular drug and potential
users were deﬁned as patients with a diagnosis corre-
sponding to an approved indication for that drug but
no drug use. They found that change in volume was
the primary driver of increased spending for the seven
diseases they studied. In particular, increase in disease
prevalence and in the number of prescriptions per
patient for new drugs were the two most important
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factors accounting for the growth in pharmaceutical
expenditures.
Berndt [3] used aggregate sales data to decompose
pharmaceutical expenditure growth in the USA into
three components: 1) price growth of incumbent prod-
ucts; 2) quantity growth of incumbent products; and
3) expenditures on new products. Between 1987 and
1994, price growth of incumbent products accounted
for about half of the total expenditure growth. Never-
theless, from 1994 through 2000, price growth
accounted for only 20% of expenditure growth. The
remaining 80% was attributable to quantity growth of
incumbent drugs and expenditures on new drugs. His
ﬁnding suggests that price increases have become a
relatively less important factor in explaining the
growth of the US pharmaceutical expenditures since
the mid-1990s. Rather, quantity growth, either from
increased demand for incumbent or new drugs, has
become the primary determinant of expenditure
growth, which is consistent with the studies by Dubois
et al. [2]. Berndt’s analysis further indicated that this
quantity growth was driven by increased drug insur-
ance beneﬁt coverage and enhanced marketing efforts,
especially direct-to-consumer advertising.
Morgan [19] used Canadian data to decompose the
change in per capita prescription drug expenditures
from 1985 to 1999 into four components: 1) the
pattern of exposure to drugs across therapeutic catego-
ries; 2) the mix of drugs used within therapeutic cat-
egories; 3) the price of unchanged products; and 4) the
rate of generic drug product selection. He found
that the above-mentioned ﬁrst three factors worked
together led to a per capita expenditure growth from
$49 to $150 per quarter over the period of study.
Nevertheless, generic substitution resulted in a saving
in per capita spending of $14 per quarter during the
study’s observational period.
Thus, net increased spending was $87 per quarter.
For the expenditure growth of $101 which was driven
by increases in both price and quantity, the increase in
price accounted for 22% of increased spending, indi-
cating that price increases have also had a relatively
minor role in explaining growth of pharmaceutical
expenditure in Canada. Rather the primary cause of
increased spending was quantity growth, a result con-
sistent with other studies [2,3]. Morgan emphasized
that the major economic forces behind the quantity
growth were an increase in the rate of exposure to a
given therapeutic category of drugs and changes in the
mix of drugs used within therapeutic categories with
these factors being of almost have equal importance
and together accounting for 78% of the expenditure
growth in Canada.
Addis and Magrini [20] used data from Italy to
decompose the growth of pharmaceutical expenditures
into three components: 1) quantity (expressed in term
of deﬁned daily doses, DDDs); 2) price; and 3) a
change in product mix, a change in expenditures
because of the shift within the same therapeutic group
of drugs toward more or less expensive products. In
Italy, drug expenditure increased 13.5% from 2000 to
2001. Their decomposition of this growth rate showed
that the increase in quantity of prescription drugs con-
sumed (measured by DDDs) led to a 9.5% increase in
expenditure and mix effects led to the expenditure
growth by 4.8%. Price changes led to a decrease in
drug expenditure of 1%.
In spite of the wide variation in statistical methods
and data sources, existing studies provide fairly con-
sistent evidence that price is not the primary determi-
nant of increased spending in prescription drugs, but
rather the quantity growth is. Existing studies also
have identiﬁed several common factors underlying
quantity growth, including an increase in disease
prevalence, an increase in drug utilization, and a
change in the drug mix within therapeutic categories,
both working to expand treatment and to substitute
drug therapy for other forms of therapy.
Method
For this study, we employed the concepts of treatment
expansion and substitution effects and the statistical
method developed by Addis and Magrini [20] to
decompose the growth of pharmaceutical expenditure
in Taiwan. The growth of pharmaceutical expenditures
from the base period (0) to the current period (1) can
be expressed as:
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In equation 1, Qi1 and Qi0 represent quantities of the
ith prescription drug dispensed in periods 1 and 0
respectively, measured in terms of DDD. As men-
tioned, the government in Taiwan regulates reimburse-
ment prices product by product. Thus, our analysis
classiﬁed drugs by brand name. Drugs with the same
ingredient but produced by different manufacturers are
treated as different products. Pi1 and Pi0 represent the
prices of the ith drug per DDD in periods 1 and 0,
respectively. Summing the product of prices by quan-
tities for all drugs yields the total expenditure on pre-
scription drugs. The left hand side of equation 1
therefore represents the growth in pharmaceutical
expenditures from the base period (0) to the current
period (1).
Expenditure growth can be decomposed into three
components on the right side of equation 1. The ﬁrst
ratio on the right side is an index of quantity growth
between two periods. We used the DDD as the stan-
dard unit of prescription drug and hence the quantities
of prescription drugs could be summed and compared
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across different drugs and time periods. The growth of
the pure quantity of drug consumed represents the
treatment expansion effect that arises from more
people being treated or the increase in treatment inten-
sity for the same group of treated patients, such as
occurs when prescriptions per patient and/or days per
prescription increased.
The second ratio represents the Laspeyres price
index, using quantities of drugs consumed in the base
year as weights. This index measures the pure price
change between current period (1) and base period (0).
The third ratio represents an index for the mix
effect, which equals the ratio of two weighted average
prices per DDD in the current period. The numerator
of this ratio uses the quantity of drug consumed at
current period (1) as the weight to calculate the mean
price per DDD. By contrast, the denominator of this
ratio uses the quantity of drug consumed in base
period (0) as the weight to calculate the mean price per
DDD. The third ratio is not equal to 1 as long as the
quantity mixes of all drugs used in current period (Qi1)
are different to those of the base period (Qi0). Since the
drug prices within the same therapeutic group is not
uniform in Taiwan, the drug substitution that physi-
cians prescribe different brands of drugs for treating
the same disease would lead to a change in price per
DDD. Thus, this ratio represents the change in the
mean price per DDD from shifts within the same thera-
peutic groups of drugs toward more or less expensive
products. If the ratio is greater than 1, it indicates that
there is an increase in mean price per DDD resulting
from the change in the mix of quantities between the
current period and the base period. Thus, this index
represents expenditure growth because of treatment
substitution.
Data Sources
Data for this study came from two sources. First, data
on the utilization of prescription drugs came from
insurance claim ﬁles obtained from Taiwan’s BNHI
(hereafter referred to as NHI claims data). After NHI
was implemented in March 1995, and ever since, the
BNHI has maintained a national, population-based
claims database. The NHI claims data contain detailed
records on utilization of personal health-care services,
including outpatient visits, hospital admissions, and
prescription drugs. The data on prescription drugs
provide information identifying the drug (drug ID), the
anatomical therapeutic chemical (ATC) classiﬁcation
system, the reimbursement price, quantity of utiliza-
tion, total spending, and such drug characteristics as
ingredient name, brand name, dosage, and manufac-
turers for all items of drugs listed in NHI formulary.
We used NHI claims data for prescription drugs during
1997–2001 to investigate the sources of expenditure
growth between these two periods.
Second, data on DDD came from Kao et al. [21]. In
that study, DDD for prescription drugs used in Taiwan
was classiﬁed according to the guidelines developed by
the World Health Organization (WHO) Collaborating
Center for Drug Statistics Methodology [22]. The
DDD is deﬁned as the assumed mean maintenance
dose per day for a drug used for its main indication in
adults [22]. This provided a standard unit of measure-
ment invariant to price and formulation. Nevertheless,
DDDs are not established for all drugs. There are no
DDDs for certain drugs, such as topical products, sera,
vaccines, antineoplastic agents, allergen extracts,
general and local anesthetics and contrast media [22].
Thus, we only included drugs with a DDD assignment
into our analysis. Among 21,931 items of drugs (in
brand names) listed in NHI formulary, Kao et al. [21]
assigned DDDs for 13,295 drugs.
After merging NHI claims data with DDD data by
individual drug ID, we ﬁrst transformed the quantity
of drug consumption in terms of DDD according to the
following equation:
Q q DDDi i i= (2)
where qi indicates the quantity of drug utilization for
the ith drug (by brand name) in terms of its package
unit obtained from NHI claims data, and Qi indicates
the quantity of drug utilization for the ith drug
expressed in terms of DDD; using the concept of DDD,
we could aggregate across drugs. We then calculated
price per DDD using
P E Qi i i= (3)
where Ei indicates the expenditure for the ith drug
obtained from NHI claims data, and Pi represents the
price per DDD for the ith drug.
After computing quantity and price expressed in
terms of DDD, we applied the method depicted in
equation 1 to decompose the sources of expendi-
ture growth into three components: 1) price; 2) quan-
tity; and 3) mix effects. In our analysis, the base
period refers to 1997 and the current period refers to
2001.
Results
Table 3 shows our results. For simplicity, we set the
index of base year (1997) equal 1. For all drugs, the
index of drug expenditure grew to 1.56 in 2001, indi-
cating that nominal pharmaceutical expenditures
increased 56% during the 5-year period or, equiva-
lently, an average annual rate of growth of 11.86%.
This growth rate far exceeded the annual growth rate
of overall health-care expenditures and gross domestic
product in Taiwan during this period.
The decomposition reveals that the price index
decreased from 1 in 1997 to 0.82 in 2001 or an 18%
decrease in the price per DDD. As mentioned above,
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Taiwan adopted a system of direct controls on reim-
bursement prices for pharmaceuticals. During our
study period, the BNHI cut the reimbursement price
twice (in 1999 and 2001) for nearly 10,000 drug prod-
ucts [11]. BNHI had two justiﬁcations for its policy: 1)
to offset increasing expenditures from adding new
drugs to its formulary; and 2) to reduce proﬁt margins
earned by providers. Therefore, it is not surprising that
prices decreased.
In contrast to the decreases in prices, the quantity
index increased from 1 in 1997 to 1.2 in 2001, imply-
ing that the quantity of prescription drugs consumed
(measured in terms of DDD) increased 20% during
our study period. This quantity growth comes from
two sources: 1) incumbent products; and 2) new prod-
ucts. Nevertheless, the approach we used could not
separate these two sources.
Further, as seen in Table 3, the mix effect was 1.59
in 2001, suggesting that the weighted average price per
DDD increased 59% during 1997–2001 as a result of
drug substitution within therapeutic groups of drugs.
Thus, the treatment substitution effect is the dominant
driver of increased spending in Taiwan.
There are two major factors that led to treatment
substitution. First, during the study period, the BNHI
cut the reimbursement price twice for selected drugs.
The reduction in reimbursement prices for selected
products in turn led to a change in proﬁt margin
earned by the provider and hence created an incentive
for providers to change the prescription formulary or
to renegotiate the acquisition price with the manufac-
turers. To increase proﬁt margins, providers have an
incentive to substitute the incumbent drugs with higher
reimbursement prices for those with lower reimburse-
ment prices, other things being equal. This substitution
may occur within the same ingredient but different
brands. In addition, it may occur among products with
different ingredients but within the same therapeutic
category. Our approach could not separate these two
types of substitution effect. Second, the provider also
substituted new drugs for the incumbent drugs after
the new drugs were added to the formulary.
As Addis and Magrini [20] noted, the approach we
used does not take into account the impact of intro-
ducing new drugs. Thus, we cannot know how much
that the treatment expansion (quantity growth) and
treatment substitution (mix effect) came from this
source. For this reason, we further decomposed the
source of expenditure growth by drug vintage and
ATC classiﬁcation. First, we categorize drugs into two
groups: old and new with new drugs being those
included on the formulary after 1996. As shown in
Table 3, among 13,295 drugs in our analysis, 13,068
drugs are old and 227 drugs are new. The index of
overall expenditure grew from 1 in 1997 to 25.22 in
2001 for new drugs. By contrast, during the same
period, the overall expenditure only increased 38% for
old drugs that were included in the national formulary
before 1996.
The decomposition reveals that the quantity index
for 227 new drugs increased from 1 in 1997 to 315 in
2001, representing a 314 fold increase in quantity of
consumption. Although one would expect that the
increase for new drugs would be high, it is extremely
high. Since our base period is 1997, some of the 227
new drugs reported in Table 3 may not be introduced
on the formulary at that time. In this case, the quan-
tities of consumption (in terms of DDD) for those
drugs in 1997 were zero. Thus, the very large number
of quantity index for new drugs reported in Table 3
Table 3 Index of NHI pharmaceutical expenditures in 2001 (base year 1997 = 1)
Classiﬁcation of drugs
Number of
items Total spending
Decomposition of increased spending
Price Quantity Mix
All drugs 13,295 1.56 0.82 1.20 1.59
By anatomical therapeutic chemical
Alimentary tract and metabolism 2,108 1.39 0.81 1.33 1.29
Blood and blood forming organs 637 1.71 0.82 1.13 1.84
Cardiovascular system 1,454 1.88 0.80 1.17 2.00
Dermatologicals 48 2.09 0.76 1.85 1.49
Genito urinary system and sex hormones 618 1.66 0.90 1.56 1.18
Systemic hormonal preparations, excl. sex hormones and insulins 653 1.83 0.92 1.27 1.57
Antiinfectives for systemic use 2,540 1.25 0.81 0.79 1.96
Antineoplastic and immunomodulating agents 120 2.39 0.88 1.39 1.96
Musculo-skeletal system 1,424 1.39 0.77 1.22 1.47
Nervous system 1,795 1.76 0.85 1.34 1.55
Antiparasitic products, insecticides and repellents 198 1.42 0.48 1.19 2.50
Respiratory system 1,568 1.34 0.86 1.03 1.51
Sensory organs 98 1.61 0.99 0.98 1.66
Various 34 3.10 0.56 4.83 1.15
By drug vintage
Old 13,068 1.38 0.82 1.17 1.44
New* 227 25.22 0.91 315.45 0.09
*New drugs indicate those included in the NHI formulary after 1996.
NHI, National Health Insurance.
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not only reﬂects the growth of quantity for the existing
new drugs in 1997 but also includes the effect of
adding more new drugs on the formulary between
1998 and 2001. It is apparent that the introduction of
new drugs led to a very rapid increase in pharmaceu-
tical expenditures and expenditure growth of new
drugs mainly came from quantity growth.
Second, we categorize drugs into 14 groups by ATC
classiﬁcation. The results for subgroup analysis consis-
tently indicate that treatment expansion and substitu-
tion effects were the major causes of increased
pharmaceutical expenditures. In particular, the growth
rate of expenditure for antineoplastic and immuno-
modualating agents was the highest among 14 sub-
groups, except for the group of various. Other groups
with relatively high rates of growth in expenditures
were drugs for cardiovascular system and nervous
system. These three groups of drugs share two
common characteristics: 1) they are for chronic dis-
eases; and 2) there was relatively more pharmaceutical
innovation in these subgroups. These two factors are
important for the treatment expansion and substitu-
tion effects to occur. As population ages, prevalence
rate of several chronic diseases, such as cancer, hyper-
tension, heart disease, and depressant, increase. The
introduction of new drugs leads more people to be
treated for these diseases. Also, the relatively quick
introduction of new drugs within these disease catego-
ries is more likely to induce a drug substitution in
treating established patients.
Overall, our decomposition clearly demonstrates
that the primary driver of increased spending in phar-
maceuticals is not price. Rather, treatment expansion
and substitution effects are the major determinants of
expenditure growth. Because of the limitation of our
approach, we are unable to provide the direct evidence
to show the extent of the treatment expansion and
substitution effects that is induced by pharmaceutical
innovation. Nevertheless, the decomposition of our
subgroup analysis shows that the adoption of pharma-
ceutical innovation is the primary driver for treatment
expansion and substitution effects. As reported in
Table 3, the quantity index is extremely large for the
subgroup of new drugs. Also, Table 3 shows that
quantity indexes are relatively higher for those drugs
with more pharmaceutical innovation in recent years,
such as for cardiovascular diseases, cancer, and mental
health. Therefore, our results provide a strong indica-
tion that pharmaceutical innovation is the main under-
lying cause of increased spending on pharmaceuticals.
Comparing Costs and Beneﬁts
To the extent that innovation is the major cause of the
expenditure increase, the next question is: Was the
innovation worth the increased cost?
To answer this question, we must quantify the ben-
eﬁts of new drugs. Compared to costs, beneﬁts are
more difﬁcult to quantify. First, beneﬁts are multiple-
dimensional, including at least the following four com-
ponents: 1) reductions in mortality; 2) reductions in
disability and morbidity; 3) improved quality of life,
i.e., reduced pain and suffering; and 4) improved labor
force productivity. Second, many potential health ben-
eﬁts of prescription drugs accrue in the long run. For
example, a drug for reducing blood cholesterol may
reduce heart disease prevalence several decades hence.
Therefore, the long-run effects of drugs cannot fully
be assessed until many years after such drugs are
introduced.
In spite of these difﬁculties, but given the impor-
tance of the topic, several studies have quantiﬁed
health beneﬁts of prescription drugs [6,23]. In part
reﬂecting lack of data on other outcomes, most studies
have focused on health beneﬁts from reduced mortality
[23]. To calculate beneﬁts from longevity gains, one
needs to estimate how much of the increase in life
expectancy is attributable to the introduction of new
drugs. Lichtenberg [6] investigated this issue by using
an indirect two-step approach. First, he estimated the
average effect of change in pharmaceutical innovation
on the change in probability of survival to age 65 from
a disease-speciﬁc panel database. Speciﬁcally, he tested
the hypothesis that diseases for which there has rela-
tively more pharmaceutical innovation have experi-
enced more improvements in health outcomes than
have outcomes for other diseases for which technologi-
cal progress has lagged. Second, he estimated the mean
effect of change in the probability of survival to 65 for
the whole population on the change in life expectancy
at birth using time series data. By multiplying these
two estimates, he obtained the mean effect of change in
pharmaceutical innovation on the change in life
expectancy at birth. His results showed that, between
1986 and 2000, mean life expectancy of the entire
population in his sample increased by 1.96 years. The
launch of new drugs accounted for 0.79 years, 40% of
the 1986–2000 increase in longevity, implying the
mean annual increase in life expectancy from the intro-
duction of new drugs for the period 1986–2000 is
about three weeks (52 ¥ 0.79/14).
Hsieh et al. [24] used a disease-speciﬁc panel data-
base obtained from Taiwan for the period 1985–2002
and a similar approach to estimate the effect of new
drug launches on longevity in that country. They found
that a 10% increase in the cumulative number of new
molecular entities was associated with an increase in
life expectancy at birth of approximately 0.1%. They
reported that the cumulative number of new molecular
entities increased about 50%, from 548 in 1996 to 821
in 2002, which in turn increased life expectancy by
0.5%. In 1996, the Taiwanese life expectancies for
males and females were 71.89 and 77.77, respectively
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[25]. Thus, the predicted longevity gains resulting from
new drug launches were 0.36 (71.89 ¥ 0.005) and
0.39 (77.77 ¥ 0.005) years for males and females,
respectively. During 1996–2002, the actual increase in
life expectancy was 1.33 years for males and
1.17 years for females [25]. These results imply that
new drug launches accounted for about 27% (0.36/
1.33) to 33% (0.39/1.17) of the longevity gain in
Taiwan. The mean annual increase in life expectancy
of the Taiwanese population resulting from new drug
launches was about three weeks (52 ¥ 0.36/6), similar
to Lichtenberg’s [6] estimates.
Used the estimated longevity gains from the intro-
duction of new drugs, together with the cost impact of
introducing new drugs into the formulary described
above, we computed the incremental cost-effectiveness
ratio for new drugs (Table 4). Since the estimate of the
effectiveness came from another study, the observa-
tional period is not exactly consistently with this study.
In spite of this difference in timing, the existing esti-
mate of health beneﬁt obtained from the period of
1996–2002 serves as a good proxy for the beneﬁt of
the subsequent year in 2003. As indicated above, the
BNHI, a single public payer, spent NT$16,694 million
on new drugs in 2003 (see Table 2). Thus, from the
perspective of public insurer, expenditure of new drugs
per capita was NT$725—total BNHI spending on new
drugs divided by total population in Taiwan, 23
million. The mean annual increase in life expectancy of
the entire male population resulting from the introduc-
tion of new drugs was 0.06 years (0.36/6). The ratio of
these two number is about NT$12,083 (or about
US$351 in 2003 dollars), indicating that the cost per
life-year gained resulting from the launch of new drugs
is extremely low as compared to most estimates of the
statistical value of a life-year [7,26,27].
Although Taiwan has NHI, only about two-thirds
of health-care expenditure is ﬁnanced by the public
sector. Private sector expenditures, either from out-of-
pocket payments or private supplemental health insur-
ance, account for the remaining one-third of such
expenditures. Thus, it is necessary to account for
private payments for new drugs, such as spending on
new drugs not listed in NHI formulary, if one is to
measure cost from a societal perspective. As shown in
Table 2, spending on new drugs accounted for about
21% of total pharmaceutical expenditure paid by
BNHI. Assuming that the private sector also spent this
share on new drugs and multiplying per capita phar-
maceutical expenditure by 21% yields national spend-
ing on new drug per capita as a measure of cost on
new drugs from the perspective of society as a whole.
In 2003, per capita pharmaceutical expenditure in
Taiwan was NT$5980 [28]. Thus, national spending
on new drugs per capita was NT$1256 (5980 ¥ 0.21).
Dividing this number by the longevity gain attributable
to new drug launches, the cost per life-year gained was
NT$20,933 (or US$608 in 2003 dollars) from a soci-
etal perspective.
As noted by Pauly [29], there are debates on correct
measurement of drug costs from a societal perspective.
Most researchers used average wholesale price (AWP)
as the measure of cost from a societal perspective.
Nevertheless, this practice is controversial because
AWP may include the excess proﬁt of the pharmaceu-
tical manufactures which is a transfer payment instead
of true “cost” to the society. Moreover, as mentioned,
providers in Taiwan earn the proﬁt margin between the
reimbursement and the acquisition prices. Thus, the
per capita pharmaceutical expenditure may overesti-
mate the true cost from a societal perspective. Because
of the lack of reliable data on the proﬁt margin, the
result reported in Table 4 overestimates the cost on
new drugs from the perspective of society as a whole.
Similarly, the measurement of beneﬁts reported in
Table 4 is subjected to estimate biased. Since we only
considered beneﬁts in the form of mortality reductions
and excluded other beneﬁts of new drugs, such as
improved quality of life and labor force productivity,
our cost-effectiveness calculation underestimated the
beneﬁt of including new drugs on the formulary. By
contrast, we may have overestimated the beneﬁt of
longevity gains resulting from the launches of new
drugs given that the determinants of mortality reduc-
tion are a very complex [30]. Although, as Hsieh et al.
[24] acknowledged, they only partially controlled for
other determinants of mortality reduction with the
ﬁxed-effects and random-effects models, there may still
be unobservable characteristics not accounted for in
their analysis. In particular, Lichtenberg [6] noted that
other technological advances other than in the phar-
maceutical sphere may have co-occurred and were not
explicitly captured by the analysis. Thus, the longevity
gain resulting from new drug launches may be overes-
Table 4 The incremental cost effectiveness ratio of new drug launches in Taiwan
Perspective of
measuring
cost
Cost (spending
on new drug
per capita)
(NT$)
Effectiveness (average
annual increase in life
expectancy attributable
to new drug launches)
Cost-effectiveness
ratio (cost per
life-year
gained, NT$)
Public insurer (BNHI) 725 (US$21.06) 0.06 12,083 (US$351)
Society as a whole 1,256 (US$36.49) 0.06 20,933 (US$608)
Note:The exchange rate of US$/NT$ was 34.42 in 2003. Number in parenthesis is cost expressed in terms of US$.
BNHI, Bureau of National Health Insurance.
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timated if the researcher simply uses the cumulative
number of drug approved with new molecular entities
as a measure of pharmaceutical innovation.
To correct the potential bias in quantifying beneﬁts,
Lichtenberg [6] took only one-third of the estimated
effect of new drugs on longevity gain to calculate the
cost per life- year gained from the launch of new drugs.
This correction was based on the evidence that US
pharmaceutical R&D expenditure accounts for about
one-third of national health R&D expenditure. Thus,
it is plausible that the remaining two-thirds of esti-
mated effect of new drugs on longevity gain may be
attributable to other medical innovations.
Using the same approach by dividing mean annual
increase in life expectancy by three yields a cost per
life-year gained resulting from new drug launches of
US$1053 from the perspective of public insurer and
US$1824 from the societal perspective. These esti-
mates are still far lower than most estimates of the
value of a statistical life-year. Also, our estimates on
cost per life-year gained resulting from the launches of
new drugs are lower than that estimated by Lichten-
berg [6] (US$6750). Health beneﬁts of new drug
launches in Taiwan are almost the same as in other
countries, but the per capita pharmaceutical expendi-
ture in Taiwan was lower than that for the USA used in
Lichtenberg’s calculations.
Conclusion
This study used two different approaches to investigate
the effect of adopting pharmaceutical innovation on
the growth of drug expenditure. First, we described the
growth of public expenditure resulting from the intro-
ducing new drugs into the formulary. Our analysis
indicates that during 1996–2003, the single public
insurer in Taiwan added 399 new drugs to the national
formulary. In 2003, total expenditure on these 399
new drugs was NT$16,694 million, accounting for
21% of total public spending in pharmaceuticals.
Second, we employed a statistical method to decom-
pose the growth of public pharmaceutical expenditures
into three components: 1) quantity (treatment expan-
sion); 2) mix (treatment substitution); and 3) pure
price effects. We found that during the period from
1997 to 2001 the public expenditure on pharmaceuti-
cals grew about 57%. The primary determinants of
this expenditure growth were treatment expansion and
treatment substitution. Prices of pharmaceuticals
declined during this period.
Overall, our analysis provides evidence consistent
with existing literature, namely that price is not the
primary driver of increased spending [2,3,19,20].
Rather the introduction of new drugs onto the formu-
lary leads to treatment expansion and substitution,
which in turn boosts spending. We therefore further
compared the cost and beneﬁt of introducing new
drugs into the formulary. Combining an estimated
beneﬁt from an existing study with our estimate of
cost, we found that cost per life-year gained resulting
from the introduction of new drugs was US$1053
from the perspective of public insurer and US$1824
from the societal perspective, far lower than estimates
of the value of a statistical life-year.
Our ﬁndings have three implications for public
policy. First, price regulation is not an effective
approach for controlling pharmaceutical expenditures.
Although our study shows that the direct regulation on
reimbursement prices did reduce the rise of prices
below that which would have otherwise occurred, it
did not reduce overall pharmaceutical expenditure. By
contrast, there are many side effects of using price
regulation for cost containment, including the launch
delay for new drug and disincentive for innovation
[10,16]. Furthermore, in a health-care system in which
providers are in a position to proﬁt directly from pre-
scribing drugs, cost containment by cutting regulated
prices often alters proﬁt margins between the reim-
bursement and acquisition prices. This in turn creates
an incentive to substitute drugs toward products with
higher proﬁt margins. From a clinical view point, the
unjustiﬁed substitution between drugs may adversely
affect quality of care, a potential adverse side effect we
did not measure.
Second, overall adoption of pharmaceutical inno-
vations is worth the increased cost of new drugs.
Although introducing new drugs on the national for-
mulary increased public outlays on pharmaceuticals,
adoption of pharmaceutical innovations also in-
creases longevity. Our conservative estimate suggests
that cost per life-year gained resulting from the
introduction of new drugs from the societal perspec-
tive was US$1,824, only about 1.8% of value of
a statistical life-year at US$100,000 widely used in
literature [7].
Third, although the adoption of pharmaceutical
innovation as awhole is cost- effective, all newdrugs are
not equally beneﬁcial relative to their costs, as noted by
Skinner et al. [31] that technological change in medi-
cine is not always worth it. This study presents an
average effect and does not imply that every new drug is
cost-effective. Our analysis has documented that the
cost impact of introducing a new drug into the formu-
lary is very signiﬁcant. Facing substantial budgetary
pressures, policymakers often postpone the introduc-
tion of new drugs or reduce the prices of the new drugs
at introduction. Our results suggest that such strategies
are likely to be unwise as an overall strategy. An effec-
tive solution for the policy dilemma between control-
ling health-care budget and improving the health of
population is a systematic analysis of the costs versus
beneﬁts of each new drug before introduction. Some
governments throughout the world have used the
method of economic evaluation to systematically
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evaluate the value of new drugs before including them
into the formulary [32]. By contrast, Taiwan has not yet
formally implemented this approach. Such evaluation
represents a promising approach for boosting the value
of public spending still further.
Source of ﬁnancial support: No funding was received for this
research.
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